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Abstract
Background: Australian Aboriginal peoples and Torres Strait Islanders (Indigenous Australians) smoke at much
higher rates than non-Indigenous people and smoking is an important contributor to increased disease, hospital
admissions and deaths in Indigenous Australian populations. Smoking cessation programs in Australia have not had
the same impact on Indigenous smokers as on non-Indigenous smokers. This paper describes the protocol for a
study that aims to test the efficacy of a locally-tailored, intensive, multidimensional smoking cessation program.
Methods/Design: This study is a parallel, randomised, controlled trial. Participants are Aboriginal and Torres Strait
Islander smokers aged 16 years and over, who are randomly allocated to a ‘control’ or ‘intervention’ group in a 2:1
ratio. Those assigned to the ‘intervention’ group receive smoking cessation counselling at face-to-face visits, weekly
for the first four weeks, monthly to six months and two monthly to 12 months. They are also encouraged to
attend a monthly smoking cessation support group. The ‘control’ group receive ‘usual care’ (i.e. they do not receive
the smoking cessation program). Aboriginal researchers deliver the intervention, the goal of which is to help
Aboriginal peoples and Torres Strait Islanders quit smoking. Data collection occurs at baseline (when they enrol)
and at six and 12 months after enrolling. The primary outcome is self-reported smoking cessation with urinary
cotinine confirmation at 12 months.
Discussion: Stopping smoking has been described as the single most important individual change Aboriginal and
Torres Strait Islander smokers could make to improve their health. Smoking cessation programs are a major priority
in Aboriginal and Torres Strait Islander health and evidence for effective approaches is essential for policy
development and resourcing. A range of strategies have been used to encourage Aboriginal peoples and Torres
Strait Islanders to quit smoking however there have been few good quality studies that show what approaches
work best. More evidence of strategies that could work more widely in Indigenous primary health care settings is
needed if effective policy is to be developed and implemented. Our project will make an important contribution in
this area.
Trial Registration: Australian New Zealand Clinical Trials Registry (ACTRN12608000604303)
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While Australian Aboriginal peoples and Torres Strait
Islanders (Indigenous Australians) historically had access
to nicotine containing plants growing naturally, heavy use
was presumably rare. However the addictive nature of
nicotine was readily exploited by Europeans [1], with
tobacco being supplied as part of rations on cattle stations
and missions until the 1960s [2]. Tobacco smoking is now
normalised in Indigenous Australian society [1]. In 2007,
the prevalence of smoking in the non-Indigenous popula-
tion was 19% [3]. In the 2004 National Aboriginal and
Torres Strait Islander Health Survey, 52% of Indigenous
Australians reported being smokers [4]. In contrast, the
2007 National Drug Strategy Household Survey reported
that 34% of Indigenous Australians were smokers [3]
whereas the current prevalence is estimated to be in excess
of 45% [5]. Over 35% of Indigenous Australian people
aged between 12 and 17 report regular smoking and
smoking prevalence increases with age [6,7]. This early
regular tobacco consumption can lead to increased depen-
dence upon nicotine and reduces the success of cessation
attempts later in life [8]. A number of reports indicate that
Indigenous Australians are less likely to stop smoking
compared with non-Indigenous people [9].
Smoking among Aboriginal peoples and Torres Strait
Islanders contributes significantly to higher rates of hos-
pitalisation and death from tobacco-related conditions
and poorer self-reported health [10-12]. Much of the
health disparity between Indigenous and non-Indigenous
people in Australian is attributable to conditions that
are either due to or made worse by tobacco consump-
tion. Smoking substantially increases the risk of both
macrovascular and microvascular complications of dia-
betes and may have a role in the development of type 2
diabetes [10]. Indigenous health professionals are
reported to be more likely to smoke than non-Indigen-
ous health professionals and to have lower rates of
awareness about the detrimental effects of smoking
behaviour [13].
Helping established tobacco smokers to stop smoking
and maintain this is notoriously difficult in any setting.
Interventions to help smokers to quit have, even in the
controlled setting of experimental randomised con-
trolled trials (RCTs), a success rate of at most 25% at 12
months and are more typically substantially lower. The
quit rates in primary health care settings, particularly
when health workers approach clients to quit, are likely
to be lower than in settings where clients have specifi-
cally sought help [2]. Motivation to quit prior to being
involved in an intervention did not predict success in
quitting [14,15]. Several RCTs have demonstrated that
5-22% of participants who were not interested in quit-
ting at the start of their participation had quit smoking
at the follow-up (reviewed in [16]). The data from these
studies suggest that quitting can occur among those
who appear to be relatively unmotivated smokers and
can be encouraged by intervention and the use of phar-
macotherapy (e.g. nicotine replacement therapy (NRT)).
Helping Aboriginal peoples and Torres Strait Islanders
to quit smoking is complex, due in part to the multiple
life stressors experienced by them [17], and the need to
identify and support local champions [18]. Integrated
services provided by Aboriginal Community Controlled
Health Services (ACCHS), which provide a ‘culturally
safe’ environment have been shown to be successful,
and interventions can reduce risk [19].
Given the stark and persisting health inequalities borne
by Indigenous Australians [20] - despite existing evidence-
based interventions - it is imperative research is underta-
ken in this setting to provide insights into how best to
respond to primary and secondary disease prevention.
RCTs provide high-quality research and evidence, and can
be undertaken in this setting. In 2002 Kimberley ACCHS
took part in a double blind, multi-centre, RCT that was
conducted by the National Aboriginal Community Con-
trolled Health Organisation (NACCHO Ear Health Trial)
[21]. The research methodology of this RCT placed Abori-
ginal people in control of their own research [22]. RCTs
when carried out in ACCHS need to be simple, modified
to the local setting, and embedded in primary health care
for them to be successful and sustainable.
This study aims to test the efficacy of a culturally
appropriate multidimensional intensive smoking cessa-
tion intervention provided by Aboriginal researchers in
helping Aboriginal peoples and Torres Strait Islanders
to become non-smokers.
Hypothesis
A culturally appropriate, multidimensional, intensive
smoking cessation intervention, provided by trained
Aboriginal researchers, will be more effective than cur-
rent standard practice in achieving and sustaining cessa-
tion to tobacco consumption among Aboriginal peoples
and Torres Strait Islanders.
Methods/Design
Objectives
The primary objectives of this study are to 1) develop a
locally-tailored, intensive, multidimensional smoking
cessation program utilising identified Aboriginal smok-
ing prevention officers, and 2) to determine the effec-
tiveness of this program through implementation of a
RCT comparing it with a standard primary care based
brief intervention strategy in two Kimberley ACCHS.
Secondary objectives include encouraging research inter-
est and capacity among Aboriginal health staff and to
build skills in Good Clinical Practice as they relate to
the conduct and evaluation of a RCT. The Aboriginal
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(Be Our Ally, Beat Smoking) Study.
Study design
This study is a parallel, randomised controlled study.
Participants are randomly allocated to one of two study
arms: the ‘intervention’ group who participates in the
BOABS program over 12 months, or the control group
who are allocated to ‘usual care’ (i.e. they do not partici-
pate in the BOABS program). Aboriginal researchers are
trained to deliver the BOABS program, the goal of
which is to help Aboriginal people quit smoking. Data
collection occurs at baseline (when participants enrol in
the study), and at six and 12 months following enrol-
ment. The primary outcome of interest is the proportion
of subjects who self-report smoking cessation with urin-
ary cotinine validation at 12 months. Figure 1 outlines
the flow of participants through the study.
Study populations
This study is being conducted in Derby and Kununurra
in the remote Kimberley region of far north Western
Australia (see Figure 2). The Kimberley is one of the
most isolated and sparsely populated areas of Australia
with a resident population of 29,298 [23] spread over
423,517 km
2. While Indigenous Australian people are
socioeconomically disadvantaged everywhere in Australia
[24], remote Indigenous people, including most residents
of the Kimberley and the adjacent Northern Territory
(NT), are in the lowest socioeconomic quartile of Indi-
genous people [24,25], the most disadvantaged group
within the most disadvantaged population in Australia.
The target population for this study are Aboriginal and
Torres Strait Islander smokers who resided in or near
these two towns. The sampling unit is Aboriginal and
Torres Strait Islander smokers (aged 16 years and over).
The Kimberley region extends 1100 km from east to
west and 850 km from north to south. The study sites
are Derby Aboriginal Health Service in Derby and Ord
Valley Aboriginal Health Service in Kununurra. The
centralised coordinating site is the Kimberley Aboriginal
Medical Services Council in Broome
Inclusion criteria
Participation in the trial is based on the following inclu-
sion criteria:
￿ Aboriginal and/or Torres Strait Islander
￿ ≥ 16 years of age
￿ Self-reported current smoker or quit within 2 weeks
of recruitment
￿ Thinking about cutting down or quitting smoking
￿ A regular client of Derby Aboriginal Health Service
(DAHS) in Derby or Ord Valley Aboriginal Health Ser-
vice (OVAHS) in Kununurra
Exclusion criteria
People are excluded from participation in the trial based
on the following criteria:
￿ Unable to provide informed consent
￿ A health condition that would prevent them from
completing the trial
￿ Unlikely to be available for follow up at 12 months
Randomisation: allocation, concealment and sequence
generation
Block randomisation (36 participants per block × 6
blocks) is used to randomly assign participants to Group
1 (control group) or Group 2 (intervention group). Each
site has 216 envelopes allocated. Each block has 24 par-
ticipants randomly assigned to Group 1 and 12 to
Group 2 using a computer generated random list of
dichotomous outcomes (control or intervention) gener-
ated for each site using Excel 2007 software (Microsoft,
Redmond, WA, USA). While only 5 blocks are required
an extra block is generated to allow for contingencies
that might require extra participants to be recruited.
Envelopes are filled and sealed by an individual who is
not involved with the study or its analysis. Envelopes
are kept off-site and under the supervision of adminis-
trative staff based at a centralised coordinating site (the
Kimberley Aboriginal Medical Services Council in
Broome). Allocation occurs via telephone with envelopes
being opened in sequential order for each site only once
a participant is consented and enrolled in the study,
eligibility is confirmed, an identification number is,
assigned and the first questionnaire completed.
Blinding
Due to the nature of the intervention and the 2:1
weighting of participants in the control and intervention
arms, the participants, research team and local health-
care staff know whether each participant belongs to the
control or intervention group. The staff performing the
urinary cotinine assay are unaware of the allocation.
Proposed intervention
Participants are told that they will be randomly assigned
to a group that receives ‘usual care’,o rag r o u pt h a t
receives extra support visits by an Aboriginal smoking
cessation officer, and that a questionnaire will be admi-
nistered when they enrol, and at six and 12 months fol-
lowing enrolment.
Participants assigned to the control group
Participants allocated to the control group receive the
usual practice of the service, including but not limited
to advice from clinical staff regarding the harmful effects
of smoking, advice regarding quitting, pharmacotherpay,
self-initiated follow up, and access to usual services
offered by the service (e.g. at DAHS clients are offered
Marley et al. BMC Public Health 2012, 12:232
http://www.biomedcentral.com/1471-2458/12/232
Page 3 of 9participation in lifestyle and primary prevention educa-
tion classes).
Participants assigned to intervention group
Participants allocated to the intervention group also
receive the usual health service-provided smoking cessa-
tion support, as above. In addition to this they are pro-
vided with smoking cessation counselling at face-to-face
visits, which will be scheduled weekly for the first four
weeks, monthly to 6 months and two monthly to 12
months. During the intervention the Aboriginal
researchers are to concentrate on smoking cessation.
Face-to-face follows up can take place at the clinic or
other location suitable to the participant (e.g. home,
work). While face-to-face contact is the default option,
 
  No 
No further action 
x  Tailored plan 
x  Monthly group 
meetings 
*All study participants are to receive usual health service-provided smoking cessation support from the
clinic as per normal practice 
Clinic attendance / self-referral / 
recruited outside clinic: 
“Do you smoke?” 
No 
Ask again at next visit 
x  Consent form signed 
x  Administer 1
st BOABS Smoking Checkup 
x  Baseline measurements 
x  2
nd Smoking Checkup: month 6 
x  Measurements 
Control Group*  Intervention Group* 
Randomisation 
Smoking  Not Smoking 
x  3
rd Smoking Checkup: month 12  
x  Collect urine at 12 months 
x  Measurements 
x  Follow up: monthly to 6 months 
x  Follow up: month 8 & 10 
x  Follow up: weekly first 4 weeks 
No 
Yes – refer to researcher 
Have you thought about cutting down or quitting? 
Do you want to know what we can offer? 
Yes 
Researcher to explain study & ask 
 “Do you want to take part in the study?” 
Yes 
Eligible 
Researcher to check eligibility  Not eligible 
No 
Yes 
Figure 1 Flowchart for a randomised controlled trial of a culturally appropriate, multidimensional, intensive smoking cessation
intervention provided by trained Aboriginal researchers.
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stances makes this difficult (e.g. a full-time worker may
be offered phone contact for some of the follow up vis-
its). If a participant does not attend for a follow up visit,
the Aboriginal researcher is to initiate active follow up
within 48 hours through phone or home visit to deter-
mine the reason for non-attendance and where possible
determine solutions to encourage ongoing participation.
Participants in the intervention group are also encour-
aged to participate in a monthly smoking cessation sup-
port group, which include: 1) additional smoking
cessation support and advice including cognitive and
behavioural approaches to ‘quitting’; 2) opportunities for
information sharing/sharing of barriers and solutions; 3)
a light healthy meal and 4) information sharing and
advice on other aspects of health and well-being includ-
ing management and prevention of common chronic
diseases, which will be delivered by appropriately trained
people. The group therapy occurs at both sites. This is a
rolling group, with participants continually entering and
leaving the group.
Content to be delivered by Aboriginal researchers:
￿ Individual
○ Motivational interviewing (e.g. what do you like/do
not like about smoking)
○ Triggers for smoking/diversions & strategies to
deal with them
○ Action plans - preventing and dealing with short
term relapses (termed ‘slipups’)
○ Discussion regarding the positives of smoking ces-
sation (e.g. saving money)
○ Pharmacotherapy (e.g. NRT)
○ Identification of factors driving smoking and case
management to link participants to additional non-
health service, community-based support agencies (e.
g. alcohol counselling)
○ Smoking cessation-associated weight gain - generic
discussions regarding potential weight gain and pro-
viding education and advice (e.g. ‘healthy’ eating,
exercise)
￿ With the health care clinic medical officer/general
practitioner
○ Organise weekly case conference to review all
active participants in the intervention group
￿ Monthly group meeting
○ Researcher conducted
○ Including dietician input for associated weight
control advice
￿ Service mapping and linkages
○ Identify and develop referral networks to help
address consequences of tobacco cessation and dri-
vers of tobacco consumption (e.g. alcohol, domestic
violence, stress, mental illness, weight changes, etc.)
Outcome measures
Primary endpoint:
￿ The proportion of participants who were not smok-
ing tobacco at 12 months as determined by self-report
and urinary cotinine level consistent with no recent
tobacco consumption [26].
Secondary endpoints:
￿ The proportion of participants who were not smok-
ing at 6 months as determined by self-report.
￿ The proportion of participants reporting excellent or
very good health using a self-reported health question-
naire [27].
￿ The proportion of participants who reported 20% or
greater reduction in the number of cigarettes smoked
each week.
￿ Process evaluation indicators: a mix of quantitative
and qualitative measures to assess how well the inter-
vention program was implemented according to the pro-
tocol e.g. number of ‘face-to-face’ meetings completed,
challenges and solutions in delivering the program.
Sample size
T h es a m p l es i z ee s t i m a t i o ni sb a s e do nat w o - s i d e d
alpha of 0.05, beta of 0.2 (power 0.8), ratio of interven-
tion to control participants of 1:2, and efficacy of main-
taining smoking cessation at 12 months of 3% in the
control group and 13% in the intervention group. Based
Derby
Fitzroy 
  Crossing
Halls 
Creek
Wyndam
Broome
Kununurra
Sealed Road
Unsealed Road
Pilbara
Kimberley
Western
Australia
Perth
Figure 2 Sites where the Be Our Ally Beat Smoking (BOABS)
Study is being conducted, the Kimberley, Western Australia.
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106 in the intervention group and 212 in the control
group across both sites. Using a conservative estimate of
50% of the clients being smokers, we will be recruiting
less than 20% of regular DAHS and OVAHS clients for
the trial. To take into account those lost to follow up (e.
g. deaths), the aimed sample size is 120 in the interven-
tion group and 240 in the control group across both
sites.
Recruitment strategies
Participants are being actively and opportunistically
recruited. Active recruitment is facilitated by the Project
Manager or Aboriginal researchers through incidental
encounters in the community, family and community
links. The participants do not need to see health care
staff prior to being recruited, but are referred to the pri-
mary health care clinic afterwards.
Participants are being passively recruited through
OVAHS and DAHS routine clinic visits as well as
through running dedicated Adult Health Check clinics
(’Aboriginal and Torres Strait Islander Adult Well Per-
sons Check’) for overdue clients - clients known or
found to be current smokers are offered participation in
the trial by clinic health workers: “Have you thought
about cutting down or quitting? Do you want to
know what we can offer?” (see Figure 1 for a flow dia-
gram explaining the steps involved).
Planned recruitment rate and risk of loss to follow up
We aim to recruit 12 people (approximately 8 control, 4
intervention) monthly for 15 months. This regular stag-
gered recruitment is to ensure that a maximum of 38
participants will be followed up by the four half-time
Aboriginal researchers in any one week period. This will
allow for variations to the scheduled recruitment with-
out placing too much pressure on resources. The trial
should be completed in 26 months.
As it proved difficult for participants to complete the
original six and 12 month questionnaires, an alternative,
minimal data collection tool was created. If participants
leave Derby or Kununurra the Aboriginal researchers
attempt to administer the final questionnaire by alter-
nate means (e.g. phone, Facebook) and arrange for a
local health care clinic to collect urine samples.
If recruitment of 360 participants (120 intervention
and 240 control) is proving difficult within the time
frame of the trial, an interim analysis of primary end-
points will be performed. It should be noted that the
requirement for an interim analysis will be at the discre-
tion of the investigators and anticipated speed of
recruitment. If required, an interim analysis is to be
undertaken by the Data Safety and Monitoring Commit-
tee (DSMC) once 50% of the participants (60 in the
intervention and 120 in the control group) have com-
pleted the study. If this demonstrates a difference that is
deemed by the DSMC to be statistically and clinically
significant then the DSMC will provide advice to the
supervising Human Research Ethics Committees
(HREC) regarding whether the trial should be
terminated.
Withdrawal criteria
Participants may be withdrawn from the study if one or
more of the following occurs:
￿ Voluntary withdrawal: a participant can voluntarily
withdraw at any time without having to provide a rea-
son for doing so
￿ Death
￿ Significant illness requiring prolonged hospitalisation
￿ A serious and irreconcilable protocol violation (as
determined by the investigators)
Data management
All information is initially recorded by Aboriginal
researchers on paper forms. Paper records are stored
under numerical code in a locked filing cabinet only
accessible to study personnel. All information collected
from participants are treated as strictly confidential.
Administrative staff will then transpose this information
to a password-protected Access 2007 database (Micro-
soft, Redmond, WA, USA). De-identified data will be
stored in password protected computers.
Data monitoring
The DSMC is an ad hoc committee to be convened in
the event of an expected adverse event, serious adverse
event or protocol deviation. Any change or alteration
from the procedures stated in the study protocol, con-
sent document, recruitment process, or study materials
(e.g. questionnaires) originally approved by the HREC
are considered to be protocol deviations. Notification to
the DSMC and reporting of the DSMC to the supervis-
ing HREC will occur if there is 1) any unexpected medi-
cal event in a participant involved in the trial as per the
streamlined reporting scheme recommended by the
National Health and Medical Research Council
(NHMRC) and Australian Health Ethics Committee [28]
or 2) a protocol deviation.
All recorded information will be assessed at least
monthly by the Project Manager. The data stored on
the relational database described above will be randomly
assessed to make sure there are no errors in
transcribing.
Data analyses
Data from the trial will be entered into the database
described above and then extracted into Stata, version
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questionnaire data will be descriptive and utilise univari-
ate parametric and non-parametric analysis to identify
differences between the control and intervention group
and the intervention group prior to and following the
intervention.
Baseline characteristics
All known potential confounders will be measured at
baseline, including sex, age, education level, marital sta-
tus, and smoking status of partner and other household
members. Thus, comparisons of the intervention and
control groups will be performed both unadjusted and
adjusted for these known confounders. This second
adjusted analysis will control for any maldistribution
after randomisation of the confounders between the two
groups.
Treatment effects
Analysis of the primary outcome will involve comparing
the quit rate between the two groups. Simple unadjusted
rates and 95% confidence intervals will be obtained in
the first instance, with subsequent multiple regression
analysis adjusting for other variables. Two forms of
regression analysis will be considered for the primary
outcome - logistic and Cox proportional hazard. Analy-
sis of secondary outcomes will be conducted using stan-
dard statistical procedures applicable to categorical or
continuous data. All tests of significance will be two-
tailed.
Procedures to account for missing data
Analysis will be on an intention-to-treat basis. A sensi-
tivity analysis will be conducted for all participants who
are lost to follow-up, with the assumption that none of
them quit compared to all of them quitting at 12
months. An additional analysis will assume that partici-
pants in the intervention group who cannot be followed
up will have the same quit rate as the control group.
Participants who die during the trial will be excluded
from the analysis.
Ethics
The trial will be conducted in compliance with the pro-
tocol, the principles of Good Clinical Practice, the
NHMRC National Statement on Ethical Conduct in
Human Research (2007), NHMRC Australian Code for
the Responsible Conduct of Research (2007), and
NHMRC Values And Ethics: Guidelines For Ethical
Conduct In Aboriginal And Torres Strait Islander
Health Research (2003) [29-31]. This trial has ethical
approval from The University of Western Australia
HREC and the Western Australian Aboriginal Health
Information and Ethics Committee, and support from
the Kimberley Aboriginal Health Planning Forum Kim-
berley Research Subcommittee.
Trial management
The Project Manager is responsible for the day to day
management of the trial. The Project Manager’sr e s p o n -
sibilities include meeting regularly with the Aboriginal
researchers and investigators, keeping copies of all docu-
mentation including details of standard care at DAHS
and OVAHS and any changes to the standard Kimberley
Smoking Cessation Protocol, making sure that the data
is collected and stored properly, overseeing the recruit-
ment of participants to the study, ensuring the randomi-
sation and allocation process is complying with the
protocol, recruit participants, administer the question-
naires and carry out follow ups if required, ensure pro-
ject targets for participant enrolment and follow up are
being met, and provide administrative support for the
project.
The Aboriginal researchers will recruit participants,
administer the questionnaires, carry out follow ups, keep
copies of the questionnaires in a locked filing cabinet,
and organise weekly case conferences with a clinic gen-
eral physician and review all active participants in the
intervention group.
Protocol deviations
Modification of the participant selection criteria and
removing the Stages of Change model from the Protocol
A major selection criteria for this trial was that potential
participants were required to be at the ready stage of
the Stages of Change Model (i.e. considering quitting
smoking soon / within the next 30 days). This model
hypothesises that the process of someone quitting smok-
ing is cyclical with smokers passing through the stages
of NOT READY, UNSURE, READY, and quitting
(MAINTENANCE), rather than a discreet event [32-34].
In this model smokers are thought to cycle through the
stages of being ready, quitting and relapsing 3 to 4
times before successfully quitting long-term. The propo-
nents of this model also suggest that interventions
should be designed according to the stage the partici-
pants are at [33].
We found that this criterion is too restrictive and that
very few Aboriginal peoples and Torres Strait Islanders
in Derby and Kununurra fulfil the criteria for being at
the ‘READY’ to quit smoking stage as we operationalised
it, although a much larger number are interested in
quitting. As detailed in the background, studies suggest
that quitting can occur in what appear to be relatively
unmotivated smokers and can be encouraged by inter-
vention and the use of pharmacotherapy (reviewed in
[16]). We therefore applied to the DSMC and supervis-
ing HREC to modify the selection criterion to include a
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or quitting, so that we would be more likely to meet our
sample size and to access a broader more appropriate
target population.
Discussion
Aboriginal peoples and Torres Strait Islanders smoke at
much higher rates than non-Indigenous people and
smoking is an important contributor to increased dis-
ease, hospital admissions and deaths in Indigenous Aus-
tralian populations. Quit smoking programs in Australia
have not had the same impact on Indigenous Australian
smokers as on non-Indigenous smokers. A range of stra-
tegies have been used to encourage Indigenous people
to quit smoking however there have been few good
quality studies that show what approaches work best.
More evidence of strategies that could work more
widely in Indigenous Australian primary health care set-
tings is needed if good policy is to be developed and
implemented. This culturally appropriate, multidimen-
sional, intensive smoking cessation intervention, which
is provided by trained Aboriginal researchers in a
remote Australian setting, has been designed to provide
high quality evidence as to its efficacy. Part of the pro-
cess of implementing high quality research pertinent to
the health care needs of Aboriginal peoples and Torres
Strait Islanders and to supporting a culture of translat-
ing such research into sustainable health care delivery
requires support from the communities and health ser-
vices involved. The involvement of Aboriginal commu-
nity-controlled health services in projects such as this
ensures local ownership, facilitates implementation, aids
knowledge translation and builds local research capacity.
The addition of a process evaluation of this study will
provide important information about the type of
research models that can work within ACCHS.
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